Updated:
Pitango Venture Capital
Chemi Peres and Rami Kalish built Pitango into Israel's largest VC fund, backing companies from seed to growth across three dedicated vehicles.
Pitango Venture Capital
Pitango Venture Capital is an SEC-registered investment adviser in Road Town, Tortola, since 2017. It is based there.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Tel Aviv
Corporate office
Herzliya, Israel
Principals
Nechemia (Chemi) J. Peres
Managing Partner & Co-Founder
Rami Kalish
Managing Partner & Co-Founder
Eyal Niv
Managing Partner | First
Aaron Mankovski
Managing Partner | Growth
Isaac Hillel
Managing Partner | Growth
Ayal Itzkovitz
Managing Partner | First
Ittai Harel
Managing Partner | HealthTech
Hila Karah
Managing Partner | HealthTech
Sector focus
Frequently asked questions
How is Pitango structured across different investment stages?
Pitango operates three dedicated funds: Pitango First for seed and early-stage, Pitango Growth for venture and late-stage, and Pitango HealthTech for seed through growth in health-related sectors. Each fund is run by a focused managing partner team but shares the firm's centralized operational, legal, and marketing resources. This structure aims to provide continuity for portfolio companies as they mature without forcing founder turnover in investor relationships.
What sectors does Pitango explicitly avoid?
Pitango's website does not specify prohibited sectors. The firm's stated focus areas for its core funds are generative AI, cybersecurity, quantum computing, TransitTech, fintech, DevOps, cloud infrastructure, and e-commerce. Pitango HealthTech concentrates on digital health, medical devices, diagnostics, foodtech, agtech, and biotech. The firm encourages founders outside these categories to reach out, suggesting an open but guided mandate rather than a rigid negative screen.
Who runs investment decisions at Pitango?
Investment decisions are handled by an eight-person managing partner group. Nechemia (Chemi) J. Peres and Rami Kalish are Co-Founders and Managing Partners. Eyal Niv and Ayal Itzkovitz lead the First fund; Aaron Mankovski and Isaac Hillel lead Growth; and Ittai Harel and Hila Karah lead HealthTech. This distributed leadership structure places individual fund decision-making with domain-dedicated partners.
Does Pitango participate in fund commitments or only direct deals?
Pitango's public materials describe it exclusively as a direct investor in technology companies across seed, early, and growth stages. There is no mention of fund-of-funds commitments or LP investments in other venture firms. The firm emphasizes its operational value-add and network for direct portfolio companies, which is consistent with a pure direct-investment venture capital model.
How does Pitango source proprietary deal flow?
Pitango attributes its deal flow to 30 years of accumulated network effects within Israeli tech, including relationships with repeat entrepreneurs, venture partners, and strategic limited partners. The firm highlights specific venture partners—including Pascal Cagni (former Apple executive) and Amir Faintuch (former GlobalFoundries executive)—who expand sourcing into global operating ecosystems. The centralized platform also funnels early-stage deal flow into the First fund, which can later feed the Growth fund.
Does Pitango maintain philanthropic structures, and how are they separated?
There is no publicly disclosed information about a dedicated philanthropic vehicle tied to Pitango. The Peres family is independently associated with the Peres Center for Peace and Innovation, but the firm's website does not reference this in connection with Pitango's investment activities. The separation between family philanthropic interests and the venture capital firm appears complete in public documentation.
What is Pitango's known posture on co-investments alongside external GPs?
Pitango presents itself as a lead investor that brings its full platform resources to bear on portfolio companies. The firm does not publicly outline a structured co-investment program for external LPs or GPs. Given its three decades of operation and the breadth of its LP network, co-investment opportunities likely arise on a deal-by-deal basis, but there is no standardized disclosure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: